Treatment.com: Quietly Powering the Future of Clinical AI

How Treatment.com is quietly building a smarter medical brain for the 21st century

In the crowded world of healthcare AI, where grand claims often outpace clinical proof, Treatment.com AI Inc. is taking a slower, more surgical approach. While rivals race to bolt generative models onto medical chatbots, Treatment—ticker TREIF on the OTC market—is building something more foundational: a vetted, physician-built digital brain trained on the actual practice of medicine.

The company’s crown jewel is the Global Library of Medicine (GLM), a continuously expanding, peer-reviewed diagnostic engine created in collaboration with physicians and academic partners. Unlike LLMs that rely on probabilistic guesses, the GLM is rooted in structured clinical logic, drawing from more than 10,000 expert-reviewed conditions and validated through OSCE-style testing—a benchmark in medical education. In one recent evaluation, the system achieved a 92% diagnostic accuracy rate.

That’s not a hypothetical stat. Treatment’s technology is already being deployed in the field: powering virtual care platforms in underserved communities, assisting clinicians with triage and diagnostics, and automating OSCE evaluations for medical students at the University of Minnesota. Their telehealth partner, Rocket Doctor, has seen adoption in both Canada and the U.S., supporting over half a million patients.

Still, the company remains a microcap—recently trading at around $0.34 per share with a market cap near $25 million. But beneath that modest valuation lies a multi-pronged strategy that speaks to a larger ambition: not just to compete in the AI healthcare arms race, but to rewrite how digital medicine gets delivered.

The Real Market Is Clinical Trust

The broader healthcare AI sector is booming. Global investment in medical AI is expected to top $187 billion by 2030, driven by rising costs, clinician shortages, and the need for scalable diagnostics. But this same explosion has created noise. Many startups enter the space by slapping a medical wrapper onto general-purpose AI tools. The result? A flood of unregulated chatbots that lack real-world utility—and in some cases, risk lives.

Treatment takes a different path. “The problem isn’t access to answers—it’s knowing which ones to trust,” said CEO John Fraser in a recent shareholder update. “That’s why we built the GLM with doctors, not just data.”

This commitment to clinical-grade accuracy has enabled Treatment to engage with institutions often cautious about AI adoption. In China, they’ve inked a major licensing partnership with Aiyibotong to bring GLM-based clinical decision support to over 200 hospitals and clinics. In the U.S., they’re targeting state-level Medicaid programs, university hospitals, and pharmacy kiosk networks in New York City.

A Platform, Not a Product

What’s striking about Treatment’s model is its scope. The GLM serves as a foundational layer for multiple applications: diagnostic triage, automated medical education, insurance coding, and even AI-powered voice assistants for remote care. That positions the company not as an app builder, but as a platform company—one with layered monetization across clinical, educational, and consumer verticals.

This platform thesis has helped attract funding even in a tight capital market. Earlier this year, Treatment raised C$3.3 million in a brokered placement, citing strong institutional demand. The company has recently went from the pre-revenue stage to generating revenue in Canada and the US with Rocket Doctor – which has recently increased its revenue and growth potential via deals in California and New York with the potential to grow even further with other similar deals. Also, it now holds enough capital to scale key pilot programs across North America and Asia.

The timing may be right. As U.S. regulators begin to sharpen their focus on clinical AI tools, systems like the GLM—designed from day one for transparency and auditability—could find themselves on the right side of the compliance wave.

A Long Game with Real Stakes

For now, Treatment.com flies under most investors’ radar. It’s not flashy, and it’s not trying to ride the hype cycle. But that may be its edge. In a sector riddled with speculation, its patient, academically-rooted strategy has real staying power.

Whether it becomes a platform adopted across medical schools, telehealth providers, and global health systems remains to be seen. But one thing is clear: if the next wave of medical AI is going to be trusted by doctors—not just patients—it will need to look more like Treatment, and less like a chatbot.